12 Best Strong Buy Stocks to Invest in According to Wall Street

Published on September 29, 2025 at 1:58 am by Noor Ul Ain Rehman in Hedge Funds, News

In this article, we will look at the 12 Best Strong Buy Stocks to Invest in According to Wall Street.

On September 26, Peter Boockvar, chief investment officer at One Point BFG Wealth Partners, appeared on CNBC to talk about the likelihood of the Federal Reserve’s interest rate cuts, new inflation data, and more.

His take on the situation is that the problem is that the core PCE remains stuck around 3%, and it’s really “tying” the central bank’s hands. He does not anticipate aggressive rate cuts unless the labor market really deteriorates.

He added that if there is going to be a reason for a pullback in the stock market, it is likely going to be the AI tech trade exhausting itself, along with the realization that we are in what he calls a “rate-tweaking cycle” instead of a “rate-cutting cycle.”

With these trends in view, let’s look at the best strong buy stocks to invest in according to Wall Street.

Our Methodology

We used stock screeners and TipRanks to make a list of the best Strong Buy stocks and selected the top 12 with the highest analyst upside potential. We also added the number of hedge fund holders for each stock as of Q2 2025, sourcing the hedge fund sentiment data from Insider Monkey’s database. The list is sorted in ascending order of analyst upside potential.

Note: All data was sourced on September 26.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

12 Best Strong Buy Stocks to Invest in According to Wall Street

12. Clearwater Analytics Holdings, Inc. (NYSE:CWAN)

Analyst Upside: 74.13%

Number of Hedge Fund Holders: 51

Clearwater Analytics Holdings, Inc. (NYSE:CWAN) is one of the best strong buy stocks to invest in according to Wall Street. On September 16, William Blair analyst Dylan Becker reiterated a bullish stance on Clearwater Analytics Holdings, Inc. (NYSE:CWAN), giving it a Buy rating without assigning a price target.

The analyst based the optimistic rating on the company’s future potential and strategic positioning, stating that the recent Clearwater Connect 2025 conference exhibited Clearwater Analytics Holdings, Inc.’s (NYSE:CWAN) vision for the creation of the industry’s first unified, end-to-end platform for investment management.

The analyst expects this to address the rising complexity in asset management.

Clearwater Analytics Holdings, Inc. (NYSE:CWAN) provides web-based investment portfolio accounting, reporting, and reconciliation services. The company’s operations are divided into the United States and the Rest of the World geographical segments.

11. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)

Analyst Upside: 74.25%

Number of Hedge Fund Holders: 28

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the best strong buy stocks to invest in according to Wall Street. On September 24, JPMorgan analyst Jessica Fye lowered the firm’s price target on Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) to $52 from $53 while keeping an Overweight rating on the shares.

The firm told investors that it updated Crinetics Pharmaceuticals, Inc.’s (NASDAQ:CRNX) model to reflect slightly higher spending assumptions.

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is a clinical-stage pharmaceutical company that develops and commercializes novel therapeutics for rare endocrine diseases and endocrine-related tumors.

The company’s product candidate, CRN00808, is an oral treatment for acromegaly. It is also developing other oral treatments for neuroendocrine tumors, hyperinsulinism, and Cushing’s disease.

10. The GEO Group, Inc. (NYSE:GEO)

Analyst Upside: 77.03%

Number of Hedge Fund Holders: 49

The GEO Group, Inc. (NYSE:GEO) is one of the best strong buy stocks to invest in according to Wall Street. On September 17, Noble Financial analyst Joe Gomes maintained a Buy rating on The GEO Group, Inc. (NYSE:GEO) and set a price target of $35.00.

The rating came after The GEO Group, Inc. (NYSE:GEO) announced on September 16 that the Florida Department of Corrections issued “Notices of Intent to Award three managed-only contracts to GEO for the assumption of management and support services at the 985-bed Bay Correctional and Rehabilitation Facility and the 1,884-bed Graceville Correctional and Rehabilitation Facility and for the continuation of management and support services at the 985-bed Moore Haven Correctional and Rehabilitation Facility.”

The GEO Group, Inc. (NYSE:GEO) designs, finances, develops, and supports services for processing centers, secure facilities, and community re-entry facilities. Its operations are divided into the following segments: US Secure, Electronic Monitoring and Supervision, Re-entry, and International Services.

The US Secure Services segment comprises the US-based public-private partnership correction and detention segment, while the Electronic Monitoring and Supervision Services segment offers services in the US.

The International Services segment offers public-private partnership secure services operations in South Africa and Australia, and the Re-entry Services Segment comprises various community-based and re-entry services.

9. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Analyst Upside: 79.20%

Number of Hedge Fund Holders: 58

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best strong buy stocks to invest in according to Wall Street. In a report released on September 17, Christopher Raymond from Raymond James maintained a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and set a price target of $85.00.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported total revenues of $825 million in fiscal Q2 2025, up 16% year-over-year and up 17% year-over-year at constant currency. GAAP diluted earnings per share (EPS) for the quarter reached $1.23.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) develops and commercializes therapies for serious and life-threatening medical conditions and rare diseases. The company’s product pipeline includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307.

8. Soleno Therapeutics, Inc. (NASDAQ:SLNO)

Analyst Upside: 84.73%

Number of Hedge Fund Holders: 52

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the best strong buy stocks to invest in according to Wall Street. On September 24, Wells Fargo analyst Derek Archila reiterated a Buy rating on Soleno Therapeutics, Inc. (NASDAQ:SLNO) and set a price target of $123.00.

Soleno Therapeutics, Inc. (NASDAQ:SLNO) reported that it used $12.6 million of cash in its operating activities during the three months ended June 30, 2025. Management reported that the company had $293.8 million of cash, cash equivalents, and marketable securities as of the end of the quarter.

Management also reported that cash at the end of Q2 “excludes $230 million of gross proceeds that the company raised in July through an underwritten offering of common stock”. Product revenue, net, for the quarter reached $32.7 million.

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is a clinical-stage biopharmaceutical company that develops and commercializes novel therapeutics to treat rare diseases. The company focuses on the treatment of neurobehavioral and metabolic disorders. Its lead candidate, Diazoxide Choline Controlled-Release (DCCR), is an oral tablet that treats Prader-Willi Syndrome (PWS).

7. MicroStrategy Incorporated (NASDAQ:MSTR)

Analyst Upside: 89.61%

Number of Hedge Fund Holders: 45

MicroStrategy Incorporated (NASDAQ:MSTR) is one of the best strong buy stocks to invest in according to Wall Street. In a report released on September 15, Gautam Chhugani from Bernstein maintained a Buy rating on MicroStrategy Incorporated (NASDAQ:MSTR) and set a price target of $600.00.

However, on September 16, Monness analyst Gustavo Gala reiterated a Sell rating on MicroStrategy Incorporated (NASDAQ:MSTR) and set a price target of $175. The same day, TD Cowen also lowered the firm’s price target on the stock to $620 from $640 while keeping a Buy rating on the shares.

The stock’s median price target of $309.06 implies an upside of 89.61% from current levels.

MicroStrategy Incorporated (NASDAQ:MSTR) engages in the development of the Bitcoin network through its operations in technology, financial markets, and advocacy. It is the world’s largest corporate holder of Bitcoin.

6. Legend Biotech Corporation (NASDAQ:LEGN)

Analyst Upside: 127.75%

Number of Hedge Fund Holders: 39

Legend Biotech Corporation (NASDAQ:LEGN) is one of the best strong buy stocks to invest in according to Wall Street. In a report released on September 12, Leonid Timashev from RBC Capital reiterated a Buy rating on Legend Biotech Corporation (NASDAQ:LEGN) and set a price target of $77.00.

Legend Biotech Corporation (NASDAQ:LEGN) reported CARVYKTI net trade sales of around $439 million in fiscal Q2 2025, with CARVYKTI demonstrating “positive long-term outcomes in the CARTITUDE-1 study with one-third of patients remaining progression-free for ≥5 years.”

Management also reported cash and cash equivalents, and time deposits of $1.0 billion as of June 30.

Legend Biotech Corporation (NASDAQ:LEGN) is a clinical-stage company that develops, discovers, manufactures, and commercializes novel therapies for oncology and other indications. It develops advanced cell therapies across an elaborate range of technology platforms. The company operates in the US, China, and other geographical segments.

5. Apogee Therapeutics Inc. (NASDAQ:APGE)

Analyst Upside: 148.56%

Number of Hedge Fund Holders: 36

Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best strong buy stocks to invest in according to Wall Street. On September 25, RBC Capital initiated coverage of Apogee Therapeutics Inc. (NASDAQ:APGE) with an Outperform rating and a $60 price target.

The firm expressed optimistic sentiments regarding the company’s potential to deliver clinically differentiated biologics, telling investors in a research note that Apogee Therapeutics Inc.’s (NASDAQ:APGE) early clinical and more recent Phase II atopic dermatitis data exhibited the beneficial properties of APG777 and its combo therapies.

RBC sees considerable revenue opportunities across several inflammation and immunology indications, supporting the optimistic rating.

Apogee Therapeutics Inc. (NASDAQ:APGE) is a biotechnology company that offers treatments for chronic obstructive pulmonary disease (COPD), atopic dermatitis (AD), and associated inflammatory and immunology (I&I) indications.

4. Immunovant, Inc. (NASDAQ:IMVT)

Analyst Upside: 174.18%

Number of Hedge Fund Holders: 31

Immunovant, Inc. (NASDAQ:IMVT) is one of the best strong buy stocks to invest in according to Wall Street. On September 3, LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Immunovant, Inc. (NASDAQ:IMVT), keeping the price target at $50.00.

Similarly, BofA analyst Jason Gerberry maintained a buy rating on the stock but lowered the firm’s price target on Immunovant, Inc. (NASDAQ:IMVT) to $30 from $33.

Leerink Partners analyst Thomas Smith also expressed bullish sentiments for Immunovant, Inc. (NASDAQ:IMVT), reiterating a Buy rating with a $52.00 price target.

The analyst consensus rating for Immunovant, Inc. (NASDAQ:IMVT) is a Strong Buy, and the stock’s median price target of $16.23 implies an upside of 174.18% from current levels.

Immunovant, Inc. (NASDAQ:IMVT) develops treatments for autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402. Both are novel antibodies targeting the neonatal fragment crystallizable receptor (FcRn).

3. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Analyst Upside: 176.82%

Number of Hedge Fund Holders: 60

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the best strong buy stocks to invest in according to Wall Street. In a report released on September 22, Kristen Kluska from Cantor Fitzgerald reiterated a Buy rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and set a price target of $105.00.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) reported $166 million in total revenue for fiscal Q2 2025, with Crysvita revenue coming up to $120 million and Dojolvi revenue reaching $23 million.

The company reaffirmed its 2025 revenue guidance, with total revenue in the $640 million to $670 million range.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) develops, acquires, and commercializes novel products to treat genetic diseases. Its product portfolio includes Crysvita, Mepsevii, Dojolvi, and Evkeeza. In 2024, the company expanded its business through four products in five indications worldwide.

2. Vaxcyte, Inc. (NASDAQ:PCVX)

Analyst Upside: 241.38%

Number of Hedge Fund Holders: 44

Vaxcyte, Inc. (NASDAQ:PCVX) is one of the best strong buy stocks to invest in according to Wall Street. Goldman Sachs initiated coverage of Vaxcyte, Inc. (NASDAQ:PCVX) on September 12 with a Neutral rating and a $38 price target.

However, Mizuho Securities analyst Salim Syed maintained a Buy rating on Vaxcyte, Inc. (NASDAQ:PCVX) on August 16, setting a price target of $163.00.

Similarly, Seamus Fernandez from Guggenheim also reiterated a Buy rating on Vaxcyte, Inc. (NASDAQ:PCVX) on August 7, setting a $116 price target.

Currently, the analyst consensus on Vaxcyte is a Strong Buy, and the stock’s median price target of $33.98 implies an upside of 241.38% from current levels.

Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage vaccine innovation company that develops high-fidelity vaccines. It develops broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. The company re-engineers the creation of highly complex vaccines through advanced chemistry and modern synthetic techniques.

1. Viking Therapeutics, Inc. (NASDAQ:VKTX)

Analyst Upside: 291.08%

Number of Hedge Fund Holders: 43

Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best strong buy stocks to invest in according to Wall Street. On September 22, BTIG analyst Justin Zelin reiterated a Buy rating on Viking Therapeutics, Inc. (NASDAQ:VKTX) and set a $125.00 price target.

The analyst based the optimistic rating on the company’s strong position in the obesity and metabolic disease market, reasoning that the recent acquisitions conducted by the large pharmaceutical companies, including the acquisition of Metsera by Pfizer, highlight the strategic significance and high valuation of the companies in the sector.

According to Zelin, Viking Therapeutics, Inc. (NASDAQ:VKTX) is considered one of the few remaining independent industry players that boast an advanced and mature portfolio, factors that make the company an attractive target for acquisitions or partnerships.

Viking Therapeutics, Inc. (NASDAQ:VKTX) is a clinical-stage company that develops therapies for metabolic and endocrine disorders.

While we acknowledge the potential of VKTX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than VKTX and that has 100x upside potential, check out our report about this cheapest AI stock.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

Headline NYSE:CWAN NASDAQ:LEGN NASDAQ:CRNX NASDAQ:RARE Show more...

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Published on May 16, 2026 at by Inan Dogan, PhD

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

175 Teslas
107 Amazons
140 Metas
84 Googles
65 Microsofts
And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

If you’re thinking about getting in, don’t wait – because once Wall Street catches wind of this story, the easy money will be gone.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Insider Monkey Ads

Buy This $3 Stock Now Before the 400% Surge Begins

Published on May 15, 2026 at by Inan Dogan, PhD

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returns! Sign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Here’s why this is a deal you can’t afford to pass up:

Access to our Detailed Report on this $3 stock with 400% upside potential.
BONUS REPORT on our #1 AI-Robotics Stock with 10000% upside potential: Our in-depth report dives deep into our #1 AI/robotics stock’s groundbreaking technology and massive growth potential.
One New Issue of Our Premium Readership Newsletter: You will also receive one new issue per month and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.
One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149
Bonus Content: Premium access to members-only fund manager video interviews
Ad-Free Browsing: Enjoy a month of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
Lifetime Price Guarantee: Your renewal rate will always remain the same as long as your subscription is active.
30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up

12 Best Strong Buy Stocks to Invest in According to Wall Street

Published on September 29, 2025 at 1:58 am by Noor Ul Ain Rehman in Hedge Funds, News

Our Methodology

12 Best Strong Buy Stocks to Invest in According to Wall Street

12. Clearwater Analytics Holdings, Inc. (NYSE:CWAN)

11. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)

10. The GEO Group, Inc. (NYSE:GEO)

9. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

8. Soleno Therapeutics, Inc. (NASDAQ:SLNO)

7. MicroStrategy Incorporated (NASDAQ:MSTR)

6. Legend Biotech Corporation (NASDAQ:LEGN)

5. Apogee Therapeutics Inc. (NASDAQ:APGE)

4. Immunovant, Inc. (NASDAQ:IMVT)

3. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

2. Vaxcyte, Inc. (NASDAQ:PCVX)

1. Viking Therapeutics, Inc. (NASDAQ:VKTX)

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Published on May 16, 2026 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up:

Buy This $3 Stock Now Before the 400% Surge Begins

Published on May 15, 2026 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up:

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Premium

Log In

Sign Up

12 Best Strong Buy Stocks to Invest in According to Wall Street

Published on September 29, 2025 at 1:58 am by Noor Ul Ain Rehman in Hedge Funds, News

Share

Our Methodology

12 Best Strong Buy Stocks to Invest in According to Wall Street

12. Clearwater Analytics Holdings, Inc. (NYSE:CWAN)

11. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)

10. The GEO Group, Inc. (NYSE:GEO)

9. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

8. Soleno Therapeutics, Inc. (NASDAQ:SLNO)

7. MicroStrategy Incorporated (NASDAQ:MSTR)

6. Legend Biotech Corporation (NASDAQ:LEGN)

5. Apogee Therapeutics Inc. (NASDAQ:APGE)

4. Immunovant, Inc. (NASDAQ:IMVT)

3. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

2. Vaxcyte, Inc. (NASDAQ:PCVX)

1. Viking Therapeutics, Inc. (NASDAQ:VKTX)

Subscribe to Insider Monkey's Free Daily Newsletter and Join 80K+ Readers

Share

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Published on May 16, 2026 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up:

Buy This $3 Stock Now Before the 400% Surge Begins

Published on May 15, 2026 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up: